王献等: 基于质谱技术的代谢组学研究及其在中国的发展

approach for the identification and isomer elucidation of biomarkers detected in a metabonomic study for the discovery of individuals at risk for diabetes by integrating the chromatographic and mass spectrometric information. Anal Chem, 2008, 80: 1280–1289

28 Gu Y, Zhang YF, Shi XZ, Li XY, Hong J, Chen J, Gu WQ, Lu X, Xu GW, Ning G. Effect of traditional Chinese medicine berberine on type

2 diabetes based on comprehensive metabonomics. Talanta, 2010, 81: 766–772

29 Hu CX, Wei H, Kong HW, Bouwman J, Gonzalez-Covarrubias V, van der Heijden R, Reijmers TH, Bao X, Verheij ER, Hankemeier T, Xu

GW, van der Greef J, Wang M. Linking biological activity with herbal constituents by systems biology-based approaches: effects of panax ginseng in type 2 diabetic Goto-Kakizaki rats. Mol Biosyst, 2011, 7: 3094–3103

30 Hu CX, Wei H, van den Hoek AM, Wang M, van der Heijden R, Spijksma G, Reijmers TH, Bouwman J, Wopereis S, Havekes LM, Verheij

E, Hankemeier T, Xu GW, van der Greef J. Plasma and liver lipidomics response to an intervention of rimonabant in ApoE*3Leiden.CETP transgenic mice. PloS One, 2011, 6: e19423

31 Huang Q, Yin PY, Wang J, Chen J, Kong HW, Lu X, Xu GW. Method for liver tissue metabolic profiling study and its application in type 2

diabetic rats based on ultra performance liquid chromatography-mass spectrometry. J Chromatogr B, 2011, 879: 961–967

32 Lehmann R, Zhao XJ, Weigert C, Simon P, Fehrenbach E, Fritsche J, Machann J, Schick F, Wang JS, Hoene M, Schleicher ED, Häring HU,

Xu GW, Niess AM. Medium chain acylcarnitines dominate the metabolite pattern in humans under moderate intensity exercise and support lipid oxidation. PloS One, 2010, 5: e11519

33 Li X, Luo XX, Lu X, Duan JG, Xu GW. Metabolomics study of diabetic retinopathy using gas chromatography-mass spectrometry: a

comparison of stages and subtypes diagnosed by Western and Chinese medicine. Mol Biosyst, 2011, 7: 2228–2237

34 Li X, Xu ZL, Lu X, Yang XH, Yin PY, Kong HW, Yu Y, Xu GW. Comprehensive two-dimensional gas chromatography/time-of-flight

mass spectrometry for metabonomics: biomarker discovery for diabetes mellitus. Anal Chim Acta, 2009, 633: 257–262

35 Lucio M, Fekete A, Weigert C, Wagele B, Zhao XJ, Chen J, Fritsche A, Häring HU, Schleicher ED, Xu GW, Schmitt-Kopplin P, Lehmann

R. Insulin sensitivity is reflected by characteristic metabolic fingerprints: a Fourier transform mass spectrometric non-targeted metabolomics approach. PloS One, 2010, 5: e13317

36 Wang C, Kong HW, Guan YF, Yang J, Gu JR, Yang SL, Xu GW. Plasma phospholipid metabolic profiling and biomarkers of type 2

diabetes mellitus based on high-performance liquid chromatography/electrospray mass spectrometry and multivariate statistical analysis. Anal Chem, 2005, 77: 4108–4116

37 Yang J, Xu GW, Hong QF, Liebich HM, Lutz K, Schmulling RM, Wahl HG. Discrimination of type 2 diabetic patients from healthy

controls by using metabonomics method based on their serum fatty acid profiles. J Chromatogr B, 2004, 813: 53–58

38 Yuan KL, Kong HW, Guan YF, Yang J, Xu GW. A GC-based metabonomics investigation of type 2 diabetes by organic acids metabolic

profile. J Chromatogr B, 2007, 850: 236–240

39 Zhao XJ, Fritsche J, Wang JS, Chen J, Rittig K, Schmitt-Kopplin P, Fritsche A, Häring HU, Schleicher ED, Xu GW, Lehmann R.

Metabonomic fingerprints of fasting plasma and spot urine reveal human pre-diabetic metabolic traits. Metabolomics, 2010, 6: 362–374 40 Zhao XJ, Peter A, Fritsche J, Elcnerova M, Fritsche A, Häring HU, Schleicher ED, Xu GW, Lehmann R. Changes of the plasma

metabolome during an oral glucose tolerance test: is there more than glucose to look at? Am J Physiol Endocrinol Metab, 2009, 296: E384–E393

41 Huang Q, Tan YX, Yin PY, Ye GZ, Gao P, Lu X, Wang HY, Xu GW. Metabolic characterization of hepatocellular carcinoma using

nontargeted tissue metabolomics. Cancer Res, 2013, 73: 4992–5002

42 Tan YX, Yin PY, Tang L, Xing WB, Huang Q, Cao D, Zhao XJ, Wang WZ, Lu X, Xu ZL, Wang HY, Xu GW. Metabolomics study of

stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis. Mol Cell Proteomics, 2012, 11: M111.010694

43 Ye GZ, Zhu B, Yao ZZ, Yin PY, Lu X, Kong HW, Fan F, Jiao BH, Xu GW. Analysis of urinary metabolic signatures of early hepatocellular

carcinoma recurrence after surgical removal using gas chromatography-mass spectrometry. J Proteome Res, 2012, 11: 4361–4372

44 Chen J, Zhang XY, Cao R, Lu X, Zhao SM, Fekete A, Huang Q, Schmitt-Kopplin P, Wang YS, Xu ZL, Wan XP, Wu XH, Zhao NQ, Xu CJ,

Xu GW. Serum 27-nor-5 beta-cholestane-3, 7, 12, 24, 25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer. J Proteome Res, 2011, 10: 2625–2632

45 Yang Q, Shi XZ, Wang Y, Wang WZ, He HB, Lu X, Xu GW. Urinary metabonomic study of lung cancer by a fully automatic hyphenated

hydrophilic interaction/RPLC-MS system. J Sep Sci, 2010, 33: 1495–1503

46 Li HY, Wang SM, Liu HM, Li J, Han D, Bu SS, Zhang MZ. Analysis of modified nucleosides in the urine of patients with malignant cancer

by liquid chromatography/electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom, 2008, 22: 3161–3171

47 Wang WZ, Feng B, Li X, Yin PY, Gao P, Zhao XJ, Lu X, Zheng MH, Xu GW. Urinary metabolic profiling of colorectal carcinoma based

728